Jin10 data reported on April 3rd that Jinhe Bio opened with a limit rise. In terms of news, to respond to U.S. tariffs, the company plans to increase the price of its oxytetracycline premix products. In this regard, a reporter called Jinhe Bio, and the staff stated that the price increase would be comprehensively considered based on specific tariff situations and the company’s product gross profit margin, and prices would be adjusted appropriately and timely. When discussing market share, the staff revealed that the company and Charoen Pokphand are the main producers of oxytetracycline, with the company’s global share currently exceeding approximately 50%.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Proposed price increase for chlortetracycline premix product, Jinhui Biological responds.
Jin10 data reported on April 3rd that Jinhe Bio opened with a limit rise. In terms of news, to respond to U.S. tariffs, the company plans to increase the price of its oxytetracycline premix products. In this regard, a reporter called Jinhe Bio, and the staff stated that the price increase would be comprehensively considered based on specific tariff situations and the company’s product gross profit margin, and prices would be adjusted appropriately and timely. When discussing market share, the staff revealed that the company and Charoen Pokphand are the main producers of oxytetracycline, with the company’s global share currently exceeding approximately 50%.